Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer

Cell Reports

Volumn 15, Issue 7, 2016, Pages 1493-1504

  Chaluvally Raghavan, Pradeep ^a,b   Jeong, Kang Jin ^a   Pradeep, Sunila ^a   Silva, Andreia Machado ^a   Yu, Shuangxing ^a   Liu, Wenbin ^a   Moss, Tyler ^a   Rodriguez Aguayo, Cristian ^a   Zhang, Dong ^a   Ram, Prahlad ^a   Liu, Jinsong ^a   Lu, Yiling ^a   Lopez Berestein, Gabriel ^a   Calin, George A ^a   Sood, Anil K ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 551B 3P; RNA POLYMERASE II; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; MIRN-551 MICRORNA, HUMAN; NUCLEAR PROTEIN; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 3Q; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN RNA BINDING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANIMAL; CELL PROLIFERATION; CELL SELF-RENEWAL; CELL SURVIVAL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; NEOPLASM; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SELF RENEWAL; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MICE, NUDE; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA POLYMERASE II; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR BURDEN; TWIST-RELATED PROTEIN 1; UP-REGULATION;

EID: 84964941322     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.04.034     Document Type: Article

References (33)

1. Abubaker K., Luwor R.B., Escalona R., McNally O., Quinn M.A., Thompson E.W., Findlay J.K., Ahmed N. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front. Oncol. 2014, 4:75.
2. Ambros V. MicroRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
4. Bell D., Berchuck A., Birrer M., Chien J., Cramer D.W., Dao F., Dhir R., DiSaia P., Gabra H., Glenn P., et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
5. Burgos-Ojeda D., Rueda B.R., Buckanovich R.J. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012, 322:1-7.
6. Cernilogar F.M., Onorati M.C., Kothe G.O., Burroughs A.M., Parsi K.M., Breiling A., Lo Sardo F., Saxena A., Miyoshi K., Siomi H., et al. Chromatin-associated RNA interference components contribute to transcriptional regulation in Drosophila. Nature 2011, 480:391-395.
7. Chaluvally-Raghavan P., Zhang F., Pradeep S., Hamilton M.P., Zhao X., Rupaimoole R., Moss T., Lu Y., Yu S., Pecot C.V., et al. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 2014, 26:863-879.
8. Eder A.M., Sui X., Rosen D.G., Nolden L.K., Cheng K.W., Lahad J.P., Kango-Singh M., Lu K.H., Warneke C.L., Atkinson E.N., et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102:12519-12524.
9. Farh K.K., Grimson A., Jan C., Lewis B.P., Johnston W.K., Lim L.P., Burge C.B., Bartel D.P. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 2005, 310:1817-1821.
10. Hennessy B.T., Lu Y., Gonzalez-Angulo A.M., Carey M.S., Myhre S., Ju Z., Davies M.A., Liu W., Coombes K., Meric-Bernstam F., et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin. Proteomics 2010, 6:129-151.
11. Huang V., Qin Y., Wang J., Wang X., Place R.F., Lin G., Lue T.F., Li L.C. RNAa is conserved in mammalian cells. PLoS ONE 2010, 5:e8848.
12. Huang V., Place R.F., Portnoy V., Wang J., Qi Z., Jia Z., Yu A., Shuman M., Yu J., Li L.C. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012, 40:1695-1707.
13. Huang V., Zheng J., Qi Z., Wang J., Place R.F., Yu J., Li H., Li L.C. Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. PLoS Genet. 2013, 9:e1003821.
14. Janowski B.A., Younger S.T., Hardy D.B., Ram R., Huffman K.E., Corey D.R. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 2007, 3:166-173.
15. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., Sood A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
16. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
17. Li L.C., Okino S.T., Zhao H., Pookot D., Place R.F., Urakami S., Enokida H., Dahiya R. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 2006, 103:17337-17342.
18. Ma Y., Zhang X., Xu X., Shen L., Yao Y., Yang Z., Liu P. STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells. PLoS ONE 2015, 10:e0124924.
19. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 2013, 15:338-344.
20. Mermel C.H., Schumacher S.E., Hill B., Meyerson M.L., Beroukhim R., Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011, 12:R41.
21. Mills G.B., May C., McGill M., Roifman C.M., Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988, 48:1066-1071.
22. Mills G.B., May C., Hill M., Campbell S., Shaw P., Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J. Clin. Invest. 1990, 86:851-855.
23. Nanjundan M., Nakayama Y., Cheng K.W., Lahad J., Liu J., Lu K., Kuo W.L., Smith-McCune K., Fishman D., Gray J.W., Mills G.B. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007, 67:3074-3084.
24. Piriyapongsa J., Bootchai C., Ngamphiw C., Tongsima S. microPIR: an integrated database of microRNA target sites within human promoter sequences. PLoS ONE 2012, 7:e33888.
25. Place R.F., Li L.C., Pookot D., Noonan E.J., Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. USA 2008, 105:1608-1613.
26. Portnoy V., Huang V., Place R.F., Li L.C. Small RNA and transcriptional upregulation. Wiley Interdiscip. Rev. RNA 2011, 2:748-760.
27. Rosen D.G., Mercado-Uribe I., Yang G., Bast R.C., Amin H.M., Lai R., Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006, 107:2730-2740.
28. Rupaimoole R., Ivan C., Yang D., Gharpure K.M., Wu S.Y., Pecot C.V., Previs R.A., Nagaraja A.S., Armaiz-Pena G.N., McGuire M., et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 2016, Published online January 4, 2016. 10.1038/onc.2015.492.
29. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21:99-102.
30. Tothill R.W., Tinker A.V., George J., Brown R., Fox S.B., Lade S., Johnson D.S., Trivett M.K., Etemadmoghadam D., Locandro B., et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 2008, 14:5198-5208. Australian Ovarian Cancer Study Group.
31. Wen W., Wu J., Liu L., Tian Y., Buettner R., Hsieh M.Y., Horne D., Dellinger T.H., Han E.S., Jove R., Yim J.H. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol. Cancer 2015, 14:100.
32. Yang L., Moss T., Mangala L.S., Marini J., Zhao H., Wahlig S., Armaiz-Pena G., Jiang D., Achreja A., Win J., et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol. 2014, 10:728.
33. Zhang Y., Fan M., Zhang X., Huang F., Wu K., Zhang J., Liu J., Huang Z., Luo H., Tao L., Zhang H. Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs. RNA 2014, 20:1878-1889.